| 000 | 01832 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516202936.0 | ||
| 264 | 0 | _c20141017 | |
| 008 | 201410s 0 0 eng d | ||
| 022 | _a1744-8069 | ||
| 024 | 7 |
_a10.1186/1744-8069-10-21 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLi, Na | |
| 245 | 0 | 0 |
_aInhibition of G protein-coupled P2Y2 receptor induced analgesia in a rat model of trigeminal neuropathic pain. _h[electronic resource] |
| 260 |
_bMolecular pain _cMar 2014 |
||
| 300 |
_a21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAction Potentials _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aFace _xinnervation |
| 650 | 0 | 4 |
_aGene Expression Regulation _xdrug effects |
| 650 | 0 | 4 |
_aHyperalgesia _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPain _xdrug therapy |
| 650 | 0 | 4 |
_aPotassium Channels _xgenetics |
| 650 | 0 | 4 |
_aPurinergic P2Y Receptor Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Purinergic P2Y2 _xgenetics |
| 650 | 0 | 4 |
_aSensory Receptor Cells _xdrug effects |
| 650 | 0 | 4 |
_aSkin _xinnervation |
| 650 | 0 | 4 |
_aSuramin _xtherapeutic use |
| 650 | 0 | 4 |
_aTrigeminal Ganglion _xcytology |
| 650 | 0 | 4 |
_aTrigeminal Nerve Diseases _xcomplications |
| 650 | 0 | 4 |
_aUridine Triphosphate _xadverse effects |
| 700 | 1 | _aLu, Zhan-ying | |
| 700 | 1 | _aYu, Li-hua | |
| 700 | 1 | _aBurnstock, Geoffrey | |
| 700 | 1 | _aDeng, Xiao-ming | |
| 700 | 1 | _aMa, Bei | |
| 773 | 0 |
_tMolecular pain _gvol. 10 _gp. 21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1744-8069-10-21 _zAvailable from publisher's website |
| 999 |
_c23652247 _d23652247 |
||